

## **Pancreatic Safety of Sitagliptin in the TECOS Trial**

John B. Buse, MD, PhD,<sup>1</sup> M. Angelyn Bethel, MD,<sup>2</sup> Jennifer B. Green, MD,<sup>3</sup> Susanna R. Stevens, MS,<sup>3</sup> Yuliya Lokhnygina, PhD,<sup>3</sup> Pablo Aschner, MD,<sup>4</sup> Carlos Raffo Grado, MD,<sup>5</sup> Tsvetalina Tankova, MD, DMedSci,<sup>6</sup> Julio Wainstein, MD,<sup>7</sup> Robert Josse, MBBS,<sup>8</sup> John M. Lachin, ScD,<sup>9</sup> Samuel S. Engel, MD,<sup>10</sup> Keyur Patel, MD,<sup>11</sup> Eric D. Peterson, MD, MPH,<sup>3</sup> and Rury R. Holman, FRCP, FMedSci,<sup>2</sup> for the TECOS Study Group

1. University of North Carolina School of Medicine, Chapel Hill, NC
2. Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
3. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC
4. Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia
5. Centre Region CINVEC, Viña del Mar, Chile
6. University Specialized Hospital for Active Treatment in Endocrinology, Medical University, Sofia, Bulgaria
7. E. Wolfson Medical Center, Holon, Israel
8. St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
9. The George Washington University Biostatistics Center, Rockville, MD
10. Merck & Co., Inc., Kenilworth, NJ
11. Toronto Centre for Liver Disease, Division of Gastroenterology, University of Toronto Health Network, Toronto, Ontario, Canada

**Corresponding author:** John B. Buse, MD, PhD, Chief, Division of Endocrinology, University of North Carolina School of Medicine, CB# 7172, Burnett-Womack 8027, 160 Dental Circle, Chapel Hill, NC 27599-7172. Office: 919-966-0134 (Jill Cunnup), Fax: 919-966-6025, Mobile 919-923-6963; E-mail: [jbuse@med.unc.edu](mailto:jbuse@med.unc.edu).

**Words:** 2691 (text); tables: 2 (+2 in supplementary appendix); figures: 2

## Abstract

**OBJECTIVE:** We evaluated the incidence of acute pancreatitis and pancreatic cancer in patients with type 2 diabetes and cardiovascular disease treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i).

**RESEARCH DESIGN AND METHODS:** In TECOS, a cardiovascular safety study of sitagliptin, all suspected cases of acute pancreatitis and pancreatic cancer were collected prospectively during 3 years' median follow-up of 14,671 participants, and adjudicated blindly.

**RESULTS:** Baseline differences were minimal between participants confirmed with no pancreatic events, acute pancreatitis or pancreatic cancer. Among those randomized to sitagliptin, 23 (0.3%) versus 12 randomized to placebo (0.2%) had pancreatitis (hazard ratio 1.93 [95% CI 0.96–3.88],  $P=0.065$ ; 0.107 versus 0.056 per 100 patient-years), with 25 versus 17 events, respectively. Severe pancreatitis (two fatal) occurred in four individuals allocated to sitagliptin. Pancreatic cancer cases were numerically fewer with sitagliptin (9, 0.1%) versus placebo (14, 0.2%) (hazard ratio 0.66 [95% CI 0.28–1.51],  $P=0.32$ ; 0.042 versus 0.066 events per 100 patient-years). Meta-analysis with two other DPP-4i cardiovascular outcome studies showed an increased risk for acute pancreatitis (risk ratio 1.58 [95% CI 1.04–2.39],  $P=0.03$ ) and no significant effect for pancreatic cancer (risk ratio 0.54 [95% CI 0.28–1.04],  $P=0.07$ ).

**CONCLUSIONS:** Pancreatitis and pancreatic cancer were uncommon events with rates that were not statistically significantly different between sitagliptin and placebo groups, although numerically more sitagliptin participants developed pancreatitis and fewer developed pancreatic cancer. Meta-analysis suggests a small absolute increased risk for pancreatitis with DPP-4i therapy. (TECOS ClinicalTrials.gov number, NCT00790205).

Increased risks of pancreatitis and pancreatic carcinoma are linked to type 2 diabetes, obesity, and insulin resistance in epidemiological studies and animal models (1). Dipeptidyl peptidase-4 inhibitors (DPP-4i) have become widely adopted as effective and well-tolerated glucose-lowering agents since the introduction of sitagliptin in 2006 (2). A potential association between DPP-4i treatment and pancreatitis and pancreatic cancer was suggested in 2009, based on studies in rats carrying the human islet amyloid polypeptide transgene treated with sitagliptin, in which increased pancreatic ductal turnover, ductal metaplasia, and isolated pancreatitis were observed (3). While subsequent preclinical studies have not confirmed this finding (4,5), this potential association has triggered intense interest and clinical assessment. Pharmacovigilance efforts, epidemiological studies, and meta-analysis of randomized control studies with DPP-4i have suggested a small or no increased risk of pancreatitis (6) or pancreatic cancer (7), but they all have methodological limitations.

The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) assessed the long-term cardiovascular safety of adding sitagliptin to usual care, as compared with usual care alone, in patients with type 2 diabetes and established cardiovascular disease during a 3-year median follow-up (8). We describe the presentation, features, and incidence of pancreatitis and pancreatic cancer cases confirmed in TECOS, and perform a meta-analysis of these events with two recently reported DPP-4i cardiovascular safety trials, the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus – Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial (9,10) and the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial (11).

## **Research Design and Methods**

The TECOS trial (NCT00790205) rationale and design (12) as well as its primary outcomes and safety measures (6) have been reported previously. Briefly, 14,735 participants from 38 countries were enrolled between December 2008 and July 2012. Eligible participants were  $\geq 50$  years old with type 2 diabetes, cardiovascular disease, and HbA1c values 6.5–8.0% (48–64 mmol/mol), and on stable-dose mono- or dual-combination therapy with metformin, pioglitazone, or sulfonylurea, or insulin with or without metformin. Study subjects were randomized double-blind to sitagliptin or placebo at dosing appropriate for their estimated glomerular filtration rate (eGFR). Patients with an eGFR  $< 30$  mL/min per  $1.73\text{ m}^2$  were not eligible for enrolment. Patients with a past history of pancreatitis were not excluded. Treatment for type 2 diabetes and its comorbidities was provided by usual care providers based on local guidelines. The addition of any antihyperglycemic agents, other than a GLP-1 receptor agonist or open-label DPP-4i, was permitted, but rosiglitazone use was discouraged. The intent-to-treat (ITT) population comprised 14,671 participants with a median follow-up of 3.0 years (interquartile range, 2.3 to 3.8; maximum, 5.7). Overall, 95.1% of participants allocated to sitagliptin and 94.1% allocated to placebo completed the study, with premature study medication discontinuation occurring in 26.1% and 27.5%, respectively. Vital status was determined at study end for 97.5% of participants. The study was managed and all data adjudicated and analyzed by academic partners (Duke Clinical Research Institute and the University of Oxford Diabetes Trials Unit).

### ***Event ascertainment and adjudication***

A Clinical Events Committee (CEC) adjudicated all cases of pancreatitis and cancer reported by investigators, recorded as adverse events, or identified in source documentation for

other events. The CEC was independent of both the sponsor and the TECOS Executive Committee and remained blinded to study treatment assignment. Information related to pancreatitis events was collected systematically in the trial database, including relevant symptoms, laboratory and imaging data, concomitant medication usage, and the investigator's suspected etiology of the event. Relevant hospital and clinic records as well as laboratory and imaging reports were also requested for CEC review. All such cases were first reviewed by a gastroenterologist and then forwarded to the CEC for a second phase of independent review and finalization of adjudication. To confirm a diagnosis of acute pancreatitis, medical records or a clinical narrative prepared by the study sites had to document symptoms (abdominal pain or vomiting) and objective evidence of pancreatic inflammation – either elevated pancreatic enzymes (amylase or lipase >3 times the upper limit of normal for the assay or in patients with chronic pancreatitis, enzyme elevations >2 times the upper limit of normal) or evidence of pancreatitis documented by imaging (abdominal computed tomography, magnetic resonance imaging, or ultrasound showing diffuse and inhomogeneous gland enlargement) (see Supplementary Appendix). Confirmed cases were further characterized as either “severe” if there was evidence of organ failure (i.e., systolic blood pressure <90 mmHg, partial pressure of oxygen in arterial blood <60 mmHg, serum creatinine >2 mg/dL after rehydration or estimated gastrointestinal blood loss of >500 ml in 24 hours) or local complications demonstrated on imaging (i.e., pancreatic necrosis, abscess, or acute pseudocyst) or “mild” (8).

Information related to malignant/neoplastic events was also collected systematically in the trial database. Investigators reported classification (malignancy vs. benign neoplasm), primary site, type, stage, and extent, as well as the date of onset and whether the malignancy/neoplasm was clinically evident prior to randomization. Relevant hospital and clinic

records and laboratory, imaging, and pathology reports were requested for CEC review. All such cases were first reviewed by an oncologist and then forwarded to the CEC for a second phase of review and finalization of adjudication. Charter-defined malignancies included new malignancy or first recurrence during the study period of a previously diagnosed malignancy. All confirmed charter-defined malignancies were categorized by site or type. Confirmed pancreatic cancers were also subcategorized as pancreatic endocrine or exocrine tumors, or as uncertain types of pancreatic malignancy. No patient had both pancreatitis and pancreatic cancer confirmed during the study.

### ***Statistical analysis***

Descriptive statistics from the adjudication process are presented to provide a sense of the nature of these events in the TECOS trial. Definition of the per-protocol population is provided in the study protocol (8). Unless otherwise stated, continuous variables are summarized with median (interquartile range) and categorical variables with number and percentage. Baseline characteristics of patients who were diagnosed with pancreatitis, pancreatic cancer, or neither were compared with Wilcoxon rank sum, chi-square, and Fisher's exact tests.

Time to pancreatic event analyses used Cox proportional hazards regression models and are presented as hazard ratio (95% CI). Hazard ratios and *P*-values for treatment effect are provided for both the ITT and per-protocol populations. The ITT population includes all events regardless of treatment compliance. The per-protocol endpoints are those that occurred before a major protocol violation in patients who took at least one dose of study medication. Event rates are shown as number and events per 100 patient-years of follow-up. Kaplan–Meier rates over the

first 3 years for pancreatic events are plotted separately for sitagliptin and placebo groups in the ITT population.

Meta-analyses were performed on data from SAVOR-TIMI 53, EXAMINE, and TECOS using random effects models on summative data for pancreatitis and pancreatic cancer outcomes. Heterogeneity among studies was assessed using Cochran's Q test and I<sup>2</sup> index. Odds ratios and 95% CIs are shown with forest plots. Comprehensive Meta Analysis v. 2.0 software (Biostat, Inc., Englewood, NJ) was used for these analyses. Except where noted, data were analyzed using SAS version 9.4.

## **Results**

The ITT population comprised 14,671 individuals. Relevant baseline characteristics for the 14,613 participants who had no reported pancreatic event, 35 with confirmed pancreatitis, and 23 with confirmed pancreatic cancer are presented in the Supplementary Appendix (Supplementary Table 1). Differences in baseline characteristics between these participants were generally minimal but smoking history differed by category ( $P=0.015$ ). For those with pancreatitis, pancreatic cancer, or no pancreatic event, the proportions of participants who were current smokers were 23%, 13%, and 11%, respectively. Participants with pancreatic cancer were more likely to have smoked previously (65%) than those with pancreatitis (31%) or no pancreatic event (40%). Additionally, there was a similar imbalance with respect to racial distribution, particularly a lower representation of pancreatic cancer among Asians and perhaps an increase in pancreatitis among Blacks. The average age of those with confirmed pancreatic events was 66 years.

Confirmed acute pancreatitis events are shown in Table 1. The 7,332 sitagliptin-assigned participants had 21,508 patient-years of follow-up, whereas those assigned placebo had 21,325 patient-years of follow-up. Among participants randomized to sitagliptin, 23 (0.3% of the ITT population, 0.107 per 100 patient-years) as compared with 12 (0.2% of the ITT population, 0.056 per 100 patient-years) participants developed pancreatitis, giving a hazard ratio of 1.93 [95% CI 0.96–3.88],  $P=0.065$ ), with these participants having 25 and 17 events, respectively. Four participants in the sitagliptin group had a severe pancreatitis event (two fatal), with no severe events in the placebo group. One pancreatitis event of unknown severity was reported for placebo, with all remaining cases adjudicated as “mild” in severity.

Figure 1A shows the cumulative proportion of participants with acute pancreatitis as a function of time, with no notable differences between groups in event rates during the first 9 months. Through 3 years of follow-up, there appears to be a fairly linear rate of cases for each treatment assignment. The median time (interquartile range) to diagnosis of acute pancreatitis was 1.42 (0.80–2.66) years and 1.44 (0.54–1.94) years in the sitagliptin and placebo groups, respectively.

The characteristics of the confirmed pancreatitis events for participants allocated to sitagliptin or placebo are listed in Table 2. The majority of cases in both groups had symptoms, elevated pancreatic enzymes, and imaging evidence of pancreatitis. Investigators reported a suspected cause of pancreatitis (alcohol, biliary disease, or a previous history of pancreatitis) in 60.0% of events in sitagliptin-treated participants compared with 47.1% in placebo-treated participants; biliary disease and/or a history of pancreatitis were present in 11 of 23 patients in the sitagliptin group (13 of 25 events) compared with 2 of 12 patients in the placebo group (7 of 17 events). The number of patients without a suspected cause was similar in the two treatment



groups, 10 and 9, respectively. Additional characteristics for the four severe pancreatitis cases in the sitagliptin group are also presented in Table 2. Characteristics of cases of suspected pancreatitis referred for adjudication but not confirmed are available in the Supplementary Appendix (Supplementary Table 2).

Confirmed pancreatic cancer cases are shown in Table 1 for the ITT population with numerically fewer participants in the sitagliptin group (N=9, 0.1%, 0.042 events per 100 patient-years) compared with the placebo group (N=14, 0.2%, 0.066 events per 100 patient-years) (hazard ratio 0.66 [95% CI 0.28–1.51],  $P=0.32$ ). Pancreatic cancer resulted in death in seven of the sitagliptin cases and nine of the placebo cases. The median time to diagnosis of pancreatic cancer was 0.80 (0.48–2.36) years and 1.05 (0.59–1.27) years in the in the sitagliptin and placebo groups, respectively. Figure 1B shows the cumulative proportion of participants with pancreatic cancer as a function of time, with no notable differences between groups in event rates during the first 12 months.

The per-protocol analyses shown in Table 1 excluded relatively few confirmed cases of pancreatitis or pancreatic cancer but tended to move the hazard ratios toward unity for both of these outcomes.

Meta-analysis of the data from the three cardiovascular outcome trials with DPP-4i reported to date (Figure 2) shows a statistically significant increased risk of acute pancreatitis for DPP-4i therapy (risk ratio 1.78 [95% CI 1.13–2.81],  $P=0.01$ ) without evidence of heterogeneity. Meta-analysis for pancreatic cancer showed a non-significant effect of DPP-4i (risk ratio 0.54 [95% CI 0.28–1.04],  $P=0.07$ ) without evidence of heterogeneity.

## Conclusions

TECOS was a global, double-blind, placebo-controlled clinical trial of sitagliptin in individuals age 50 years and older with type 2 diabetes and established cardiovascular disease. It demonstrated, on a background of usual care, that there was no difference between treatment groups in the rates of major cardiovascular events, heart failure, or death from any cause. This study examined whether there was an association between use of sitagliptin and pancreatic disease.

The overall rate of confirmed acute pancreatitis was low (0.095 events per 100 patient-years) with a numerically increased but not statistically significant risk for acute pancreatitis with sitagliptin (0.107 per 100 patient-years for sitagliptin vs. 0.056 per 100 patient-years for placebo). The clinical presentation of acute pancreatitis with regard to symptoms and onset during the study period was similar in the two treatment groups. Recurrent episodes of pancreatitis occurred in two participants treated with sitagliptin (both had one recurrence) and two participants treated with placebo (one a single recurrence and one four recurrences). Cases of confirmed severe acute pancreatitis were rare, but numerically greater with sitagliptin as compared with placebo (four vs. zero, including two fatal cases). For both fatal cases, an etiology other than study treatment was suspected. Pancreatitis is often associated with multiple risk factors, and it is unclear to what extent sitagliptin contributed to the pancreatitis in each case. That said, the finding of other potential etiologies should not provide reassurance that sitagliptin was perhaps not a contributor, as the alternative hypothesis would be that sitagliptin magnifies the penetrance of risk factors on pancreatitis development and severity.

The per-protocol analysis of individuals with recent or ongoing treatment with study medication provides a similar result to the ITT analysis with a modestly lower point estimate for risk and wider CI (hazard ratio 1.80 [95% CI 0.86–3.76],  $P=0.12$ ). With the small number of

events it is not possible to ascribe particular risk factors for acute pancreatitis for the population as a whole (see Supplementary Appendix). Although a prior history of pancreatitis was not a TECOS exclusion criterion, the risk of acute pancreatitis with sitagliptin exposure in those with a prior history of pancreatitis cannot be estimated as this information was not recorded systematically at baseline.

Pancreatic cancer was also an uncommon event in the TECOS trial (0.054 events per 100 patient-years). Numerically there were fewer cases of pancreatic cancer with sitagliptin than with placebo, but the difference was not statistically significant. The per-protocol analysis for pancreatic cancer essentially eliminates the discrepancy between arms. Although the median 3-year follow-up during TECOS is longer than many other diabetes outcome trials, it is insufficient to permit a robust assessment of the long-term risk of pancreatic cancer.

SAVOR-TIMI 53 (9) and EXAMINE (11) are two recently reported, double-blind, placebo-controlled, cardiovascular safety trials of DPP-4i that evaluated saxagliptin and alogliptin, respectively. These trials have important differences compared with TECOS. Both SAVOR-TIMI 53 and EXAMINE enrolled patients with a wider HbA1c range at diagnosis and a shorter duration of study treatment exposure. SAVOR-TIMI 53 employed different criteria in the adjudication of pancreatitis, whilst EXAMINE did not adjudicate cases of pancreatitis and reported no cases of pancreatic cancer. These factors preclude head-to-head comparisons of rates of pancreatitis and could impact on the meta-analysis presented here, which means these findings should therefore be interpreted with caution.

The primary goal of TECOS was to examine the cardiovascular safety of sitagliptin. The trial demonstrated unequivocal evidence for no increased risk of major cardiovascular events, heart failure, or all-cause mortality. Sitagliptin was associated with good tolerability and

glycemic efficacy. These analyses of acute pancreatitis and pancreatic cancer from the TECOS trial, and the meta-analysis with two other large, well-conducted studies involving other members of the DPP-4i class, provide prescribers and patients greater precision around the question of pancreatic safety. Although conclusions are limited by small numbers of events over a limited period of follow-up, information collected from these double-blind, randomized, placebo-controlled trials provide the most robust data available currently to quantify the risk of pancreatic outcomes associated with DPP-4i therapy. It may be that some cases of subclinical pancreatitis could have been missed but similar findings from the three trials suggest that there is a small increased risk of acute pancreatitis with DPP-4i therapy. For sitagliptin, the magnitude of excess risk based on the results of TECOS is estimated to be approximately 1 additional case per 1000 patient-years, although severe and fatal cases did occur in the sitagliptin group. If this difference had been statistically significant, the number needed to harm would have been 1974 to have one additional affected individual with pancreatitis. Pancreatic cancer, a condition that is almost uniformly fatal, occurred in roughly half as many participants as pancreatitis, and the risk did not appear to be increased with sitagliptin. Longer-term pharmacovigilance and pharmaco-epidemiological studies of DPP-4i will be required to provide greater insights into the pancreatic safety of the class.

**Acknowledgements:** The authors wish to thank the investigators, staff, and participants in the TECOS trial without whose efforts and collaboration this work would not have been possible.

We thank the following academic partners and contract research organizations for their assistance: Parexel International, Jubilant Clinsys, Clinogent, Canadian VIGOUR Centre, Green Lane Coordinating Centre, and South Australian Health and Medical Research Institute. R.R.H. is an NIHR Senior Investigator.

**Funding:** Funded by Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc.

**Duality of Interests:** J.B.B. reports grant and fees for consultation to UNC under contract and travel/meals/lodging for contracted activities from Merck during the conduct of the study; grants and fees for consultation to UNC under contract and travel/meals/lodging for contracted activities from Eli Lilly, GI Dynamics, Amylin, Orexigen, Merck, Novo Nordisk, vTv Pharma, AstraZeneca, Takeda, Sanofi and Lexicon; fees for consultation to UNC under contract and travel/meals/lodging for contracted activities from Hoffmann-La Roche, Bristol-Myers Squibb, Liposcience, Elcylex, Metavention, Dance Biopharm and Quest; grants from Medtronic Minimed, Tolorex, Osiris, Halozyme, Pfizer, Johnson & Johnson, Andromeda, Boehringer-Ingelheim, GlaxoSmithKline, Astellas, MacroGenics, Intarcia Therapeutics and Scion NeuroStim; stock options in PhaseBio outside the submitted work; and is or has been a member of a variety of non-profit boards: American Diabetes Association, DiabetesSisters, Taking Control of Your Diabetes, AstraZeneca Healthcare Foundation, Bristol-Myers Squibb Together on Diabetes Foundation, the National Diabetes Education Program. M.A.B. has received grants, personal fees, and other support from Merck, Sharp & Dohme, other support from Boehringer-Ingelheim, Novo Nordisk, Glaxo and Smith Kline, and non-financial support from Bayer. J.B.G. has received grants from Merck Sharp & Dohme, AstraZeneca, and GlaxoSmithKline, grants and

personal fees from Merck Sharp & Dohme, other support from Boehringer-Ingelheim, and personal fees from Bioscientifica and The Endocrine Society. P.A. has received grants and personal fees from AstraZeneca, Boehringer-Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Sharpe & Dohme, Novartis, and Sanofi. T.T. has received grants and personal fees from Merck, Sharp & Dohme, Boehringer-Ingelheim, Novo Nordisk, Sanofi, Eli Lilly, Novartis, Servier, AstraZeneca. R.J. has received grants or personal fees from Merck, AstraZeneca, Janssen, and Eli Lilly. J.M.L. has received personal fees from Merck, Boehringer-Ingelheim, Gilead Pharmaceuticals, Jansen Pharmaceuticals, Eli Lilly, Novartis, and Glaxo SmithKline. S.S.E. is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. E.D.P. has received grants and personal fees from Janssen, grants from Eli Lilly, and personal fees from AstraZeneca, Bayer, and Sanofi. R.R.H. has received grants and personal fees from Merck, grants from Bayer, and AstraZeneca, personal fees from Amgen, Bayer, Intarcia, Novartis, Novo Nordisk, and other support from GlaxoSmithKline, Janssen, and Takeda. The other authors report no potential conflicts of interest.

**Author contributions:** J.B.B. drafted and edited the manuscript and contributed to the study design, data analysis and interpretation. J.B.G. edited the manuscript and contributed to the study design, event definition and adjudication, data collection, data analysis and interpretation. K.P. contributed to data interpretation, event adjudication, and editing the manuscript. S.R.S and Y.L. performed the statistical analyses and edited the manuscript. M.A.B., P.A., C.R.G., T.T., J.W., R.J., J.M.L., S.S.E., K.P., and E.D.P. edited the manuscript and contributed to the study. R.R.H. edited the manuscript, designed and ran the study, and contributed to the data analysis and interpretation. J.B.B. and R.R.H. are the guarantors of this work and, as such, had full access to

all of the data in the study and take full responsibility for the work as a whole, including the study design and integrity of the data.

**Previous presentations:** Parts of this work were presented at the American Diabetes Association and European Association for the Study of Diabetes annual meetings in 2015.

## References

1. Andersen DK, Andren-Sandberg Å, Duell EJ, et al. Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. *Pancreas* 2013;42:1227-1237.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2012;35:1364-1379.
3. Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. *Diabetes* 2009;58:1604-1615.
4. Aston-Mourney K, Subramanian SL, Zraika S, et al. One year of sitagliptin treatment protects against islet amyloid-associated  $\beta$ -cell loss and does not induce pancreatitis or pancreatic neoplasia in mice. *Am J Physiol Endocrinol Metab* 2013;305:E475-E484.
5. Chadwick KD, Fletcher AM, Parrula MC, et al. Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor in the nonclinical assessment of GLP-1-based therapies. *Diabetes* 2014;63:1303-1314.
6. Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. *Expert Opin Drug Saf* 2015;14:505-524.
7. Gokhale M, Buse JB, Gray CL, Pate V, Marquis MA, Stürmer T. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. *Diabetes Obes Metab* 2014;16:1247-1256.
8. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2015;373:232-242.
9. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med* 2013;369:1317-1326.



10. Raz I, Bhatt DL, Hirshberg B, et al. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI53) of the dipeptidyl peptidase-4 inhibitor saxagliptin. *Diabetes Care* 2014;37:2435-2441.
11. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med* 2013;369:1327-1335.
12. Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. *Am Heart J* 2013;166:983-989.

**Figure 1.** Cumulative proportion of participants with confirmed acute pancreatitis (A) and confirmed pancreatic cancer (B) by treatment group as a function of time.

**Figure 2.** Meta-analysis of pancreatitis (A) and pancreatic cancer (B) in the SAVOR-TIMI 53, EXAMINE, and TECOS trials. It is noted that SAVOR-TIMI 53 employed different criteria than TECOS for the adjudication of pancreatitis, and that in EXAMINE pancreatitis was not adjudicated and no pancreatic cancer cases were reported.

**Table 1—Confirmed pancreatitis and pancreatic cancer events in TECOS**

	Patients				Events	
	Sitagliptin (N=7332)	Placebo (N=7339)	HR (95% CI)	P	Sitagliptin	Placebo
Intent-to-treat analysis						
Acute pancreatitis	23 (0.107)	12 (0.056)	1.93 (0.96–3.88)	0.065	25 (0.113)	17 (0.077)
Severe	4	0			4	0
Mild	19	11			21	16
Unknown	0	1			0	1
Pancreatic cancer	9 (0.042)	14 (0.066)	0.66 (0.28–1.51)	0.32	...	...
Per-protocol analysis						
Acute pancreatitis	20 (0.104)	11 (0.058)	1.80 (0.86–3.76)	0.12	21 (0.109)	12 (0.063)
Pancreatic cancer	9 (0.047)	10 (0.054)	0.91 (0.37–2.25)	0.85	...	...

Data are *n* (events per 100 patient-years of follow-up) or *n*, except where indicated. Some patients had more than 1 event.

**Table 2—Characteristics of pancreatitis events among sitagliptin- and placebo-treated participants in TECOS**

Characteristic	Sitagliptin (N=25)	Placebo (N=17)
Symptoms		
Abdominal pain	22 (88%)	17 (100%)
Vomiting	11 (44%)	5 (29%)
Evidence of pancreatic inflammation		
Elevated pancreatic enzymes	15 (60%)	14 (82%)
Amylase or lipase >3× upper limit of normal	13	13
In patients with chronic pancreatitis, amylase or lipase >2× upper limit of normal	2	1
Documented by imaging	18 (72%)	7 (41%)
Investigator reported pancreatitis etiology		
Known or suspected etiology*	15 (60%)	8 (47%)
Alcohol	2	0
Biliary	9	3
History of pancreatitis	6	6
Other	1	1
Unknown†	10 (40%)	9 (53%)
Severity indices		
Severe pancreatitis	4 (16%)	0 (0%)
Evidence of organ failure‡	1	0
Local complications on imaging	4	0
Pancreatic necrosis	3	0
Pancreatic abscess	2	0
Pancreatic pseudocyst	1	0
Pancreatitis resulting in death§	2	0

Data are *n* (%) or *n*. \*Investigator reported. †Events where study drug was reported as a possible cause are included in the category for unknown. ‡The patient with evidence of organ failure had renal failure (serum creatinine >2 mg/dL after rehydration), pulmonary insufficiency (PaO<sub>2</sub> <60 mmHg), and shock (systolic blood pressure <90 mmHg). §The pancreatitis deaths occurred in one patient with an alcohol history and one with a known history of chronic biliary pancreatitis.